NCT01878812View on ClinicalTrials.gov

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older

PHASE3CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

July 11, 2013

Primary Completion Date

August 5, 2013

Study Completion Date

August 5, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

Fluarix/Influsplit Tetra® (2013-2014 season)

1 dose administered intramuscularly in the deltoid region of non-dominant arm

Trial Locations (4)

01097

GSK Investigational Site, Dresden

01099

GSK Investigational Site, Dresden

01129

GSK Investigational Site, Dresden

01309

GSK Investigational Site, Dresden

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY